Waters Corporation

Waters Corporation to Present at the Jefferies 2024 Healthcare Conference

Retrieved on: 
Lunedì, Maggio 13, 2024
Conference, Webcast, WAT, Waters Corporation

MILFORD, Mass., May 13, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2024 Healthcare Conference on Wednesday, June 5th, 2024 at 9:30AM Eastern Time.

Key Points: 
  • MILFORD, Mass., May 13, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2024 Healthcare Conference on Wednesday, June 5th, 2024 at 9:30AM Eastern Time.
  • A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com.
  • A replay of the webcast will be available for 90 days.

Waters ACQUITY QDa II Mass Detector Delivers Wider Range of Chemical Analysis within Cost-Effective, Lower Energy Instrument

Retrieved on: 
Mercoledì, Maggio 8, 2024
ACT, C-peptide, Chromatography software, Mass, Analytic, Research, LC-MS, Waters Corporation, API, Food, CDS, Mass spectrometry, WAT

MILFORD, Mass., May 8, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the release of the ACQUITY QDa II Mass Detector, the evolution of its highly successful, compact, and streamlined mass detection instrument that delivers high-quality, mass spectral data to chromatographic separations. This new and improved mass detector allows scientists to analyze a wider range of chemical entities with a robust, cost-effective, low energy consumption solution. It enhances and complements Waters best-in-class ACQUITY Premier Liquid Chromatography (LC) separations portfolio to enable flexible analysis of both small and large molecules across pharmaceutical, food, chemical, and materials applications.

Key Points: 
  • MILFORD, Mass., May 8, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the release of the ACQUITY QDa II Mass Detector, the evolution of its highly successful, compact, and streamlined mass detection instrument that delivers high-quality, mass spectral data to chromatographic separations.
  • This new and improved mass detector allows scientists to analyze a wider range of chemical entities with a robust, cost-effective, low energy consumption solution.
  • The ACQUITY QDa II Mass Detector is designed to seamlessly integrate into existing laboratory workflows with the usability and format of a LC detector.
  • The ACQUITY QDa II Mass Detector is designed for compliance-ready deployment on Waters Empower™ Chromatography Data System (CDS) Software.

Waters ACQUITY QDa II Mass Detector Delivers Wider Range of Chemical Analysis within Cost-Effective, Lower Energy Instrument

Retrieved on: 
Mercoledì, Maggio 8, 2024
ACT, C-peptide, Chromatography software, Mass, Analytic, Research, LC-MS, Waters Corporation, API, Food, CDS, Mass spectrometry, WAT, Fine chemical

MILFORD, Mass., May 8, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the release of the ACQUITY QDa II Mass Detector, the evolution of its highly successful, compact, and streamlined mass detection instrument that delivers high-quality, mass spectral data to chromatographic separations. This new and improved mass detector allows scientists to analyze a wider range of chemical entities with a robust, cost-effective, low energy consumption solution. It enhances and complements Waters best-in-class ACQUITY Premier Liquid Chromatography (LC) separations portfolio to enable flexible analysis of both small and large molecules across pharmaceutical, food, chemical, and materials applications.

Key Points: 
  • MILFORD, Mass., May 8, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the release of the ACQUITY QDa II Mass Detector, the evolution of its highly successful, compact, and streamlined mass detection instrument that delivers high-quality, mass spectral data to chromatographic separations.
  • This new and improved mass detector allows scientists to analyze a wider range of chemical entities with a robust, cost-effective, low energy consumption solution.
  • The ACQUITY QDa II Mass Detector is designed to seamlessly integrate into existing laboratory workflows with the usability and format of a LC detector.
  • The ACQUITY QDa II Mass Detector is designed for compliance-ready deployment on Waters Empower™ Chromatography Data System (CDS) Software.

Waters Corporation (NYSE: WAT) Reports First Quarter 2024 Financial Results

Retrieved on: 
Martedì, Maggio 7, 2024
Webcast, Table, Government, Waters Corporation, GAAP, EPS, Cryptocurrency

MILFORD, Mass., May 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the first quarter of 2024.

Key Points: 
  • Sales for the first quarter of 2024 were $637 million, a decrease of 7% as reported, compared to sales of $685 million for the first quarter of 2023.
  • On a GAAP basis, diluted earnings per share (EPS) for the first quarter of 2024 was $1.72, compared to $2.38 for the first quarter of 2023.
  • "Our first quarter revenues were at the high end of our guidance as our team continues to execute well," said Dr. Udit Batra, President & CEO, Waters Corporation.
  • Waters Corporation will webcast its first quarter 2024 financial results conference call today, May 7, 2024, at 8:00 a.m. Eastern Time.

Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns

Retrieved on: 
Lunedì, Aprile 22, 2024
HPS, Safety, LNP, Waters Corporation, Vaccine, Particle size, Therapy, HPLC, Patient, Laboratory, Messenger, WAT

MILFORD, Mass., April 22, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today introduced new GTxResolve Premier Size Exclusion Chromatography (SEC) 1000Å 3-micron (3 µm) Columns. Waters has implemented a unique combination of novel packing materials and MaxPeak™ Premier High-Performance Surface (HPS) technology into the columns to help scientists accelerate the development of gene-based therapeutics, including cell & gene, mRNA and LNPs.

Key Points: 
  • New line of GTxResolve™ Premier SEC Columns provide higher sensitivity, resolution, and throughput to accelerate the development of cell & gene-based therapeutics.
  • MILFORD, Mass., April 22, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today introduced new GTxResolve Premier Size Exclusion Chromatography (SEC) 1000Å 3-micron (3 µm) Columns.
  • Waters GTxResolve Premier SEC Columns support the growing demand for mRNA, LNP, and viral-vector-based therapies.
  • GTxResolve Premier SEC Columns are engineered to reduce problematic non-specific binding, minimize mobile phase method development challenges, and provide higher throughput separation efficiency.

Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns

Retrieved on: 
Lunedì, Aprile 22, 2024
HPS, Safety, LNP, Waters Corporation, Vaccine, Particle size, Therapy, HPLC, Patient, Laboratory, Messenger, WAT

MILFORD, Mass., April 22, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today introduced new GTxResolve Premier Size Exclusion Chromatography (SEC) 1000Å 3-micron (3 µm) Columns. Waters has implemented a unique combination of novel packing materials and MaxPeak™ Premier High-Performance Surface (HPS) technology into the columns to help scientists accelerate the development of gene-based therapeutics, including cell & gene, mRNA and LNPs.

Key Points: 
  • New line of GTxResolve™ Premier SEC Columns provide higher sensitivity, resolution, and throughput to accelerate the development of cell & gene-based therapeutics.
  • MILFORD, Mass., April 22, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today introduced new GTxResolve Premier Size Exclusion Chromatography (SEC) 1000Å 3-micron (3 µm) Columns.
  • Waters GTxResolve Premier SEC 1000Å 3 µm Columns address those challenges by providing higher sensitivity, resolution, and throughput by combining novel particle technology with low adsorption MaxPeak Premier HPS Technology.
  • GTxResolve Premier SEC Columns are engineered to reduce problematic non-specific binding, minimize mobile phase method development challenges, and provide higher throughput separation efficiency.

Waters Corporation Schedules First Quarter 2024 Earnings Conference Call

Retrieved on: 
Giovedì, Aprile 11, 2024
Webcast, Waters Corporation, WAT

MILFORD, Mass., April 11, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2024 financial results conference call live on Tuesday, May 7th, 2024 at 8:00 a.m. Eastern Time.

Key Points: 
  • MILFORD, Mass., April 11, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2024 financial results conference call live on Tuesday, May 7th, 2024 at 8:00 a.m. Eastern Time.
  • A live webcast of the presentation will be available on Waters Investor Relations website at h ttps://ir.waters.com .
  • A replay of the webcast will also be available until at least June 4th, 2024, at midnight Eastern Time.

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

Retrieved on: 
Martedì, Aprile 9, 2024
QA/QC, QC, WAT, Intelligence, HPLC, Laboratory, HPS, Waters Corporation

MILFORD, Mass., and MUNICH, April 9, 2024 /PRNewswire/ -- Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories. The new HPLC system combines advanced bio-separation technology and built-in instrument intelligence features. It is designed to help biopharma QC analysts boost efficiency and eliminate up to 40% of common errors, saving time lost by investigating the source of failed runs and out-of-specification results.

Key Points: 
  • New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi.
  • MILFORD, Mass., and MUNICH, April 9, 2024 /PRNewswire/ -- Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories.
  • The Alliance iS Bio HPLC System also combines with Waters compliance-ready Empower Chromatography Software to help laboratories collect, manage, and report chromatography test results.
  • It integrates seamlessly with Waters and third-party liquid chromatography instruments to help high-volume QC labs manage operational risk, mitigate disruptions, and increase overall productivity.

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

Retrieved on: 
Martedì, Aprile 9, 2024
QA/QC, QC, WAT, Intelligence, HPLC, Laboratory, HPS, Waters Corporation

MILFORD, Mass., and MUNICH, April 9, 2024 /PRNewswire/ -- Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories. The new HPLC system combines advanced bio-separation technology and built-in instrument intelligence features. It is designed to help biopharma QC analysts boost efficiency and eliminate up to 40% of common errors, saving time lost by investigating the source of failed runs and out-of-specification results.

Key Points: 
  • New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi.
  • MILFORD, Mass., and MUNICH, April 9, 2024 /PRNewswire/ -- Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories.
  • The Alliance iS Bio HPLC System also combines with Waters compliance-ready Empower Chromatography Software to help laboratories collect, manage, and report chromatography test results.
  • It integrates seamlessly with Waters and third-party liquid chromatography instruments to help high-volume QC labs manage operational risk, mitigate disruptions, and increase overall productivity.

H.I.G. Capital Acquires the Spine Business of ZimVie Rebranded as Highridge Medical

Retrieved on: 
Lunedì, Aprile 1, 2024
Banking, Software, General Health, Professional Services, Hardware, Technology, Medical Devices, Other Manufacturing, Health Technology, Finance, Other Technology, Health, Manufacturing, Culture, Boston Scientific, Growth, EVP, Partnership, Patient, Acquisition, Medtronic, H.I.G. Capital, Surgeon, Waters Corporation, CO, J&J, Management

Capital (“H.I.G.”), a leading global alternative investment firm with $60 billion of capital under management, is pleased to announce that one of its affiliates has completed the acquisition of the Spine division of ZimVie, Inc (“ZimVie”, NYSE: ZIMV).

Key Points: 
  • Capital (“H.I.G.”), a leading global alternative investment firm with $60 billion of capital under management, is pleased to announce that one of its affiliates has completed the acquisition of the Spine division of ZimVie, Inc (“ZimVie”, NYSE: ZIMV).
  • The acquired business will operate as an independent entity and has been renamed Highridge Medical (“Highridge” or the “Company”).
  • Glen Kashuba will join Highridge as the Chief Executive Officer and Rebecca Whitney will continue as President of Highridge.
  • medical device investments include Augmedics, Vertiflex (acquired by Boston Scientific), Neuwave Medical (acquired by J&J), and Intact Vascular (acquired by Philips).